ARTICLE
|
doi:10.20944/preprints202311.0688.v1
Subject:
Biology And Life Sciences,
Biochemistry And Molecular Biology
Keywords:
melanoma; metastasis; overall survival; progression-free survival; side effects; Nivolumab; Ipilimumab; anti-programmed death-1 antibodies; anti-cytotoxic T-lymphocyte antigen-4 antibodies.
Online: 10 November 2023 (11:05:56 CET)